Patrick Daly

DocwireNews

Researchers at the 83rd Scientific Sessions of the American Diabetes Association (ADA) discussed findings from an ongoing, phase 1/2, multicenter, single-arm, open-label clinical trial on VX-880, an investigational stem cell-derived islet cell therapy for patients with type 1 diabetes.According to an ADA release, 6 patients with <a href="https://www.docwirenews.com/post/outcomes-worse-for-children-with-type-1-diabetes-who-are-black">type 1 diabetes</a> who received VX-880 showed restored insulin secretion, improved glycemic control, improved time-in-range, reduction or elimination of exogenous insulin usage, and complete absence of severe hypoglycemic events (SHEs) in the 90-day evaluation period following treatment.The study enrolled adult patients with type 1 diabetes with impaired hypoglycemic awareness and severe hypoglycemia. All patients had undetectable insulin secretion and a history of recurrent SHEs in the year before treatment.<h3>Islet Cell Therapy for Diabetes Removed Need for Insulin</h3>Initially, 1 patient in part A of the study received half of the target dose, per protocol, and 1 patient in part B received the full target dose. Both patients had at least 12 months of follow-up and were eligible for the primary efficacy analysis of elimination of SHEs from day 90 to month 12 with a glycated hemoglobin (HbA1c) level of &lt;7%.Both patients were insulin independent and had over 95% time-in-range. The patient from part A had an HbA1c level of 5.3% at month 21 compared with 8.6% at baseline, and the patient from part B had an HbA1c level of 6.0% at month 12 compared with 7.6% at baseline.Following <a href="https://diabetes.org/newsroom/press-releases/2023/novel-stem-cell-derived-islet-cell-therapy-continues-show-promise-achieving-insulin-independence-individuals-type-1-diabetes">those results</a>, 3 more patients received the full target dose of VX-880 as a single infusion with up to 90 days of follow-up. The authors reported that all 3 patients also exhibited improved insulin production, reduced HbA1c levels, improved time-in-range, and reduced daily insulin usage, consistent with the trends observed in the first 2 patients.Trevor W. Reichman, MD, PhD, surgical director of pancreas and islet cell transplantation for Ajmera Transplant Centre at the University of Toronto, told the ADA, &ldquo;these new findings demonstrate the potential of stem cell-derived islets as a future treatment for patients with type 1 diabetes, signaling a new era that could potentially remove the need for exogenously administered insulin to achieve glycemic control.&rdquo;Treatment with VX-880 was generally safe and well tolerated, with a safety profile similar to immunosuppressants and cadaveric islet cell transplantations. The majority of adverse events were mild or moderate. There were no serious AEs.More From the ADA: <a href="https://www.docwirenews.com/post/diabetes-screening-in-children-predicts-future-complications">Childhood Diabetes Screening Predicts Future Diabetes-Related Complications</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Encouraging Results With Novel Type 1 Diabetes Treatment

American Diabetes Association's 83rd Scientific Sessions

ADA 2023

A novel treatment, VX-880, restored insulin secretion and reduced exogenous insulin use in patients with type 1 diabetes.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe